HPV 16 E5 oncoprotein is expressed in early stage carcinogenesis and can be a target of immunotherapy

F. Paolini, G. Curzio, M. N. Cordeiro, S. Massa, L. Mariani, F. Pimpinelli, A. C. de Freitas, R. Franconi, A. Venuti

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

HPV16 persistent infection is a well-known condition that precedes human cancer development. High risk HPV E5 proteins cooperate with E6/E7 oncogenes to promote hyper-proliferation of infected cells leading to possible cancer progression. Thus, presence of E5 viral transcripts could be a key marker of active infection and, in turn, a target of immunotherapy. Purpose of the study is to detect E5 transcripts in clinical samples and to explore the activity of novel anti-HPV16 E5 DNA vaccines. HPV transcripts were detected by PCR with specific primers encompassing the splice-donor sites of E5 transcript. For E5-based immunotherapies, 2 E5-based versions of DNA vaccines carrying whole E5 gene or a synthetic multiepitope gene were improved by fusion to sequence of PVX coat protein. These vaccines were challenged with a new luminescent animal model based on C3-Luc cell line. E5 transcripts were detected in clinical samples of women with HPV positive low-grade SIL, demonstrating the validity of our test. In C3 pre-clinical mouse model, vaccine candidates were able to induce a strong cellular immunity as indicated by ELISPOT assays. In addition, E5-CP vaccines elicited strong anti-tumor effects as showed by decreased tumor growth monitored by animal imaging. The tumor growth inhibition was comparable to those obtained with anti-E7 DNA vaccines. In conclusion, detection of E5 transcripts in clinical samples indicates that E5 is a possible target of immunotherapy. Data from pre-clinical model demonstrate that E5 genetic immunization is feasible, efficacious and could be utilized in clinical trials.
Original languageEnglish
Pages (from-to)291-297
Number of pages7
JournalHuman Vaccines and Immunotherapeutics
Volume13
Issue number2
DOIs
Publication statusPublished - Feb 1 2017

Fingerprint

Human papillomavirus 16
Oncogene Proteins
Immunotherapy
Carcinogenesis
DNA Vaccines
Vaccines
Neoplasms
Synthetic Genes
Enzyme-Linked Immunospot Assay
RNA Splice Sites
Human Development
Growth
Infection
Oncogenes
Cellular Immunity
Immunization
Animal Models
Cell Proliferation
Clinical Trials
Cell Line

Keywords

  • E5
  • HPV
  • HPV transcripts
  • cancer
  • immunotherapy
  • therapeutic vaccine

Cite this

HPV 16 E5 oncoprotein is expressed in early stage carcinogenesis and can be a target of immunotherapy. / Paolini, F.; Curzio, G.; Cordeiro, M. N.; Massa, S.; Mariani, L.; Pimpinelli, F.; Freitas, A. C. de; Franconi, R.; Venuti, A.

In: Human Vaccines and Immunotherapeutics, Vol. 13, No. 2, 01.02.2017, p. 291-297.

Research output: Contribution to journalArticle

Paolini, F. ; Curzio, G. ; Cordeiro, M. N. ; Massa, S. ; Mariani, L. ; Pimpinelli, F. ; Freitas, A. C. de ; Franconi, R. ; Venuti, A. / HPV 16 E5 oncoprotein is expressed in early stage carcinogenesis and can be a target of immunotherapy. In: Human Vaccines and Immunotherapeutics. 2017 ; Vol. 13, No. 2. pp. 291-297.
@article{d7d0a951f8584c9ba0cc4fdfceeb683d,
title = "HPV 16 E5 oncoprotein is expressed in early stage carcinogenesis and can be a target of immunotherapy",
abstract = "HPV16 persistent infection is a well-known condition that precedes human cancer development. High risk HPV E5 proteins cooperate with E6/E7 oncogenes to promote hyper-proliferation of infected cells leading to possible cancer progression. Thus, presence of E5 viral transcripts could be a key marker of active infection and, in turn, a target of immunotherapy. Purpose of the study is to detect E5 transcripts in clinical samples and to explore the activity of novel anti-HPV16 E5 DNA vaccines. HPV transcripts were detected by PCR with specific primers encompassing the splice-donor sites of E5 transcript. For E5-based immunotherapies, 2 E5-based versions of DNA vaccines carrying whole E5 gene or a synthetic multiepitope gene were improved by fusion to sequence of PVX coat protein. These vaccines were challenged with a new luminescent animal model based on C3-Luc cell line. E5 transcripts were detected in clinical samples of women with HPV positive low-grade SIL, demonstrating the validity of our test. In C3 pre-clinical mouse model, vaccine candidates were able to induce a strong cellular immunity as indicated by ELISPOT assays. In addition, E5-CP vaccines elicited strong anti-tumor effects as showed by decreased tumor growth monitored by animal imaging. The tumor growth inhibition was comparable to those obtained with anti-E7 DNA vaccines. In conclusion, detection of E5 transcripts in clinical samples indicates that E5 is a possible target of immunotherapy. Data from pre-clinical model demonstrate that E5 genetic immunization is feasible, efficacious and could be utilized in clinical trials.",
keywords = "E5, HPV, HPV transcripts, cancer, immunotherapy, therapeutic vaccine",
author = "F. Paolini and G. Curzio and Cordeiro, {M. N.} and S. Massa and L. Mariani and F. Pimpinelli and Freitas, {A. C. de} and R. Franconi and A. Venuti",
note = "LR: 20170307; JID: 101572652; OTO: NOTNLM; PMCR: 2017/12/08; ppublish",
year = "2017",
month = "2",
day = "1",
doi = "10.1080/21645515.2017.1264777 [doi]",
language = "English",
volume = "13",
pages = "291--297",
journal = "Human Vaccines and Immunotherapeutics",
issn = "2164-5515",
publisher = "Taylor and Francis Inc.",
number = "2",

}

TY - JOUR

T1 - HPV 16 E5 oncoprotein is expressed in early stage carcinogenesis and can be a target of immunotherapy

AU - Paolini, F.

AU - Curzio, G.

AU - Cordeiro, M. N.

AU - Massa, S.

AU - Mariani, L.

AU - Pimpinelli, F.

AU - Freitas, A. C. de

AU - Franconi, R.

AU - Venuti, A.

N1 - LR: 20170307; JID: 101572652; OTO: NOTNLM; PMCR: 2017/12/08; ppublish

PY - 2017/2/1

Y1 - 2017/2/1

N2 - HPV16 persistent infection is a well-known condition that precedes human cancer development. High risk HPV E5 proteins cooperate with E6/E7 oncogenes to promote hyper-proliferation of infected cells leading to possible cancer progression. Thus, presence of E5 viral transcripts could be a key marker of active infection and, in turn, a target of immunotherapy. Purpose of the study is to detect E5 transcripts in clinical samples and to explore the activity of novel anti-HPV16 E5 DNA vaccines. HPV transcripts were detected by PCR with specific primers encompassing the splice-donor sites of E5 transcript. For E5-based immunotherapies, 2 E5-based versions of DNA vaccines carrying whole E5 gene or a synthetic multiepitope gene were improved by fusion to sequence of PVX coat protein. These vaccines were challenged with a new luminescent animal model based on C3-Luc cell line. E5 transcripts were detected in clinical samples of women with HPV positive low-grade SIL, demonstrating the validity of our test. In C3 pre-clinical mouse model, vaccine candidates were able to induce a strong cellular immunity as indicated by ELISPOT assays. In addition, E5-CP vaccines elicited strong anti-tumor effects as showed by decreased tumor growth monitored by animal imaging. The tumor growth inhibition was comparable to those obtained with anti-E7 DNA vaccines. In conclusion, detection of E5 transcripts in clinical samples indicates that E5 is a possible target of immunotherapy. Data from pre-clinical model demonstrate that E5 genetic immunization is feasible, efficacious and could be utilized in clinical trials.

AB - HPV16 persistent infection is a well-known condition that precedes human cancer development. High risk HPV E5 proteins cooperate with E6/E7 oncogenes to promote hyper-proliferation of infected cells leading to possible cancer progression. Thus, presence of E5 viral transcripts could be a key marker of active infection and, in turn, a target of immunotherapy. Purpose of the study is to detect E5 transcripts in clinical samples and to explore the activity of novel anti-HPV16 E5 DNA vaccines. HPV transcripts were detected by PCR with specific primers encompassing the splice-donor sites of E5 transcript. For E5-based immunotherapies, 2 E5-based versions of DNA vaccines carrying whole E5 gene or a synthetic multiepitope gene were improved by fusion to sequence of PVX coat protein. These vaccines were challenged with a new luminescent animal model based on C3-Luc cell line. E5 transcripts were detected in clinical samples of women with HPV positive low-grade SIL, demonstrating the validity of our test. In C3 pre-clinical mouse model, vaccine candidates were able to induce a strong cellular immunity as indicated by ELISPOT assays. In addition, E5-CP vaccines elicited strong anti-tumor effects as showed by decreased tumor growth monitored by animal imaging. The tumor growth inhibition was comparable to those obtained with anti-E7 DNA vaccines. In conclusion, detection of E5 transcripts in clinical samples indicates that E5 is a possible target of immunotherapy. Data from pre-clinical model demonstrate that E5 genetic immunization is feasible, efficacious and could be utilized in clinical trials.

KW - E5

KW - HPV

KW - HPV transcripts

KW - cancer

KW - immunotherapy

KW - therapeutic vaccine

U2 - 10.1080/21645515.2017.1264777 [doi]

DO - 10.1080/21645515.2017.1264777 [doi]

M3 - Article

VL - 13

SP - 291

EP - 297

JO - Human Vaccines and Immunotherapeutics

JF - Human Vaccines and Immunotherapeutics

SN - 2164-5515

IS - 2

ER -